Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance

 

Seven Biotechnology Companies Added to the Index

 

Lenexa, KS -- June 21, 2022 -- Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy Index, a stock index of top companies developing cancer immunotherapy treatments and discovering new ways to use the body’s immune system to fight cancer. 

For the June meeting, the committee has added seven immunotherapy companies. They are Arcellx (Nasdaq: ACLX), BioNTech (Nasdaq: BNTX), Celularity (Nasdaq: CELU), IGM Biosciences (Nasdaq: IGMS), Lyell Immunopharma (Nasdaq: LYEL), NGM Biopharmaceuticals (Nasdaq: NGM), and Nkarta (Nasdaq: NKTX).

 

These companies replace ALX Oncology (Nasdaq: ALXO), Atara Biotherapeutics (Nasdaq: ATRA), Bicycle Therapeutics (Nasdaq: BCYC), Caribou Biosciences (Nasdaq: CRBU), Inhibrx (Nasdaq: INBX), MacroGenics (Nasdaq: MGNX), and Rubius Therapeutics (Nasdaq: RUBY).

Brad Loncar, CEO of Loncar Investments and Chairman of the Index Committee, had the following comments, “2022 has been very difficult for the biotechnology sector and immunotherapy companies in the capital markets. In terms of the underlying science, this year I have been encouraged to see the first ever TCR based immunotherapy approved by U.S. FDA for uveal melanoma and the first bi-specific antibody immunotherapy for cancer approved in Europe for follicular lymphoma. Furthermore, in the cell therapy space, a second CAR-T product was recently approved by U.S. FDA for multiple myeloma. We are proud to support companies that are working on innovative immunotherapy technologies such as these.”

 

Effective this week, all index holdings have been rebalanced to hold equal weight. The index is rebalanced and reconstituted semi-annually. The next rebalance will occur on December 20, 2022. 

 

Loncar Investments is an official partner of the Cancer Research Institute, the world’s longest running nonprofit organization dedicated exclusively to harnessing the immune system’s power to conquer all cancers. To learn about how to give to CRI, please visit here.

 

Why immunotherapy:  Cancer immunotherapy has become an important sector in the biotechnology space and is changing the way many cancers are treated. While traditional medicines like chemotherapies often give cancer a broad punch, the benefit of using immunotherapy is derived from the immune system's dynamic nature and the way it can more precisely be tailored to fight a patient's disease.  

 

About the index:  The Loncar Cancer Immunotherapy Index is an equal-weighted index of top immunotherapy companies rebalanced and reconstituted on a semi-annual basis. Price and return data are independently calculated on a daily basis by Indxx, LLC. Additional information can be found at the index’s dedicated website, www.LoncarIndex.com.

 

Index provider:  Loncar Investments, LLC is committed to making the biotechnology space more approachable to a wider range of investors. It incorporates extensive research into biotech companies and technologies to develop stock market indexes that are focused on precise investment opportunities. The company is principally owned by biotech investor and analyst Brad Loncar.

 

 

Contact:

Loncar Investments, LLC

Jill Tatios, 215-240-6398

Email: loncar@gregoryfca.com

Loncar Investments, LLC : P.O Box 15072, Lenexa, KS  66285 : 913-871-5007 : Not investment advice or a solicitation to buy or sell securities